Ching joined us as Senior Vice President, Chief Financial Officer in June 2017.
Prior to joining Cytokinetics, Ching served as Chief Financial Officer of North America Pharmaceuticals at Sanofi from 2015 to 2017, and as the Chair of the North America Regional Finance Council. From 2012 to 2015, Ching was Chief Financial Officer for Ventana Medical Systems, a member of the Roche Group.
Previously, between 2001 and 2012, Ching held a wide variety of finance positions with Genentech, and then Roche, following their acquisition of Genentech, including two years as Chief Financial Officer of Roche in Taiwan and as Head of R&D Finance at Genentech.
A former Army Platoon Commander and Liaison Officer in the Taiwanese Army, Ching holds a Bachelor of Science degree in Naval Architecture from National Taiwan University, a Master of Science in Aerospace Engineering from the University of Michigan, and an M.B.A. in Finance and General Management from the University of Chicago Graduate School of Business.
In his spare time, Ching and his wife Connie enjoy outdoor activities such as hiking, biking, and skiing.
What is Ching W. Jaw's net worth?
The estimated net worth of Ching W. Jaw is at least $3.35 million as of April 4th, 2022. Mr. Jaw owns 67,109 shares of Cytokinetics stock worth more than $3,346,055 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Jaw may own. Learn More about Ching W. Jaw's net worth.
How do I contact Ching W. Jaw?
Has Ching W. Jaw been buying or selling shares of Cytokinetics?
Ching W. Jaw has not been actively trading shares of Cytokinetics during the past quarter. Most recently, Ching Jaw sold 15,000 shares of the business's stock in a transaction on Monday, April 4th. The shares were sold at an average price of $40.00, for a transaction totalling $600,000.00. Following the completion of the sale, the chief financial officer now directly owns 67,109 shares of the company's stock, valued at $2,684,360. Learn More on Ching W. Jaw's trading history.
Who are Cytokinetics' active insiders?
Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.
Are insiders buying or selling shares of Cytokinetics?
During the last year, insiders at the biopharmaceutical company sold shares 43 times. They sold a total of 432,011 shares worth more than $27,490,574.11. The most recent insider tranaction occured on November, 18th when CEO Robert I Blum sold 5,000 shares worth more than $252,750.00. Insiders at Cytokinetics own 3.4% of the company.
Learn More about insider trades at Cytokinetics. Information on this page was last updated on 11/18/2024.
